Mason Street Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Mason Street Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-98,065	Closed	-$2.65M	–	1788
2014 Q4	$2.65M	Sell	98,065 -9,555	-9%	-$164K	0.02%	840
2014 Q3	$1.26M	Buy	107,620 +11,250	+12%	+$142K	0.01%	1114
2014 Q2	$1.5M	Hold	96,370	–	–	0.01%	1066
2014 Q1	$1.9M	Buy	+96,370	New	+$1.64M	0.02%	975

Other funds holding FPRX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mason Street Advisors's FPRX Position: Q1 2015 in Review

Mason Street Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2015, closing a stake of 98,065 shares — an estimated $2.65M sold.

Mason Street Advisors first reported a position in FPRX in Q1 2014 and held it in 4 quarters. The position peaked at $2.65M in Q4 2014. 93 funds tracked by Wall St. Rank hold FPRX as of Q1 2015.

Mason Street Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
Mason Street Advisors sold 98,065 Five Prime Therapeutics, Inc. shares in Q1 2015, an estimated $2.65M.
Mason Street Advisors first reported a position in Five Prime Therapeutics, Inc. in Q1 2014 and held it in 4 quarters.
Mason Street Advisors's Five Prime Therapeutics, Inc. position peaked at $2.65M in Q4 2014.
93 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2015.

Based on Mason Street Advisors's 13F filing for Q1 2015, filed 15 May 2015.